New registry tracks side effects of targeted radiation for spread cancer
NCT ID NCT04085029
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is a registry that collects information from 300 adults with metastatic cancer who receive or have received a precise, high-dose form of radiation called ablative radiotherapy. The goal is to track short-term side effects and better understand the safety of this treatment. No new drug or therapy is being tested; instead, researchers are gathering real-world data to guide future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ablative radiotherapy
- What this could lead to
- If successful, this registry could help doctors better understand the safety of ablative radiotherapy for metastatic cancer, potentially improving treatment guidelines.
- What could go wrong
- This is an observational registry, not a treatment trial. It does not test whether the therapy works, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Cancer Institute Cary
RECRUITINGCary, North Carolina, 27518, United States
-
Duke Raleigh Hospital
RECRUITINGRaleigh, North Carolina, 27609, United States
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
-
Duke Women's Cancer Care Raleigh
RECRUITINGRaleigh, North Carolina, 27607, United States
-
Durham Veterans Administration Health Care System (DVAHCS)
RECRUITINGDurham, North Carolina, 27705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tissue analysis may guide personalized cancer therapy
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Blood test vs. scalpel: could liquid biopsy replace tissue biopsies for cancer monitoring?
- Can a new nucleotide analogue boost cancer treatment?
- Zapping resistant tumors with precision radiation may extend the life of current cancer therapy
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?